incident first-ever stroke during ten years of followup) Female (n=921, mean age=70.
Incident first-ever stroke: 72 +/-8 years 655 Males, 921 Females. Incident first-ever stroke: 66 men, 85 women Male (n=655, mean education =8.0 years, SD=5.6); Female (n=921, mean education =6.9 years, SD=5.1); Education: Firstever stroke: male 7.6 (SD 5.6) years, female 7.0 (SD 5.9 years) diagnosis during following up or stroke as cause of death on death report Reitz 2006 5 Longitudinal study of Medicare recipients in northern Manhattan (1271 (Stroke cases = 97)) Mean age = 76.2 years, SD=6.0 69.6% female Mean education = 8.6 yrs, SD=4.6
Baseline data (1992) (1993) (1994) , follow up data during sequential intervals of approximately 18 months (1994-1996, 1996-1997, 1997-1999 Initial assessment from onset of stroke (baseline assessment) and then at 1 week (second set of assessments) and 2 weeks (third set of assessments) after the baseline assessment.
Second round of data collection: baseline assessment and at 1, 2, and 3 weeks after the baseline assessment in each individual.
NOT REPORTED Ben Assayag 2015 7 Tel Aviv Brain Acute Stroke Cohort (TOBASCO) Study (n -298) Mean age 66.7+/-9.6 years 62.4% male (n = 186) Mean education 13.2 (SD 3.7) years Baseline MoCA and NeuroTrax computerised cognitive testing and then repeated at 6, 12 and 24 months following the event. The average of the 6 index scores (memory, executive functions, visuospatial perception, verbal function, attention and motor skills) was computed as the global cognitive score. Interactions between time and stroke (mean differences in cognitive function) between those with and those without stroke Cognitive decline increased significantly after stroke relative to before stroke.
Cognitive decline increased 1.9 fold after incident stroke with cognitive function predicting mortality even after adjusting for stroke, demographic and health related factors. APOE e4 carriers demonstrated a non-significantly lowered risk for MMSE decline. APOE e4 associated with declines in info processing speed and small declines for immediate and delayed recall. Of the 53 stroke patients -(n=17) had the e4 allele for APOE, (n=36) did not. Stroke patients without ApoE e4 had the lowest changes in MMSE (-1.6 points). Stroke patients with e4 showed greater declines in info processing speed (-2.0 points). Reitz 2006 5 NOT REPORTED NOT REPORTED Memory declined significantly over time (β= -1.6, p=0.005), abstract/visuospatial and language performance remained stable. A history of stroke was associated with more rapid decline in memory performance over time (β=-3.6, p=0.04). There was no relation between stroke and decline in abstract/visuospatial or language performance.
Memory and abstract/visuospatial function declined at a faster rate in men or persons who lacked the APOEe4 allele with stroke compared to women or APOEe4 carriers. This remain unchanged after adjusting for age, education, ethnic group, BMI< hypertension, heart disease, diabetes and smoking.
The association between stroke and decline in memory performance was strongest for men and for persons without an APOE4 allele. A significant association between stroke and decline in abstract/visuospatial performance was also observed for persons without the APOE-e4 allele. Univariate predictors of cognitive decline 24 months from stroke include: age greater than or equal to 75, education <12 years, white matter lesion score, Modified Rankin score 6 months after stroke, MoCA score at hospital admission, MoCA score 6 months after stroke, Berg Balance Scale 6 months after stroke (<50), the Timed Up and Go test score 6 months after stroke (>12 seconds), number of correct answers during dual-task 6 months after stroke (<15). Multivariate predictors include age greater than or equal to 75 years, TUG score (> 12secs) 6 months after stroke, MoCA score 6 months after stroke Balance and gait are significant risk markers for cognitive status and impaired cognitive recovery after mild stroke or TIA Univariate predictors of cognitive decline 24 months from stroke include: age greater or equal to 75 years, education <12 years, ischaemic heart disease, hypertension, white matter lesion score, MoCA score at hospital admission, MoCA score 6 months after stroke Computerised global cognitive score at admission and 6 months post-stroke, GDS score at admission and 6 months posts-stoke. Multivariate predictors include MoCA at admission, age greater or equal to 75 and admission GDS score greater than or equal to 6
Depressive symptoms in poststroke/TIA patients are associated with MCI or dementia and functional deterioration at 2-year follow-up. This association occurs immediately after stroke/TIA and becomes more significant 6 months after the initial stroke.
GDS > or equals 6: 91.3 (9. Of the n=104, 61 (59%) were classified as cognitively impaired at baseline, compared to 52 (50%) at follow up. In total, 45 were classed as cog. Impaired at both occasions (persistent cases), 7 of the non-impaired at baseline switched to impaired at follow up, 16 were classed as cognitively impaired at baseline but switched to non-impaired at follow up (recovery cases) A significant dose-dependent effect of the APOE-genotype in relation to overall post-stroke cognitive functioning was found at baseline and follow-up, but not pre-stroke. The e4 carriers showed a significant decline in tests related to verbal learning and memory compared to the non-carriers.
Four factors at baseline were independently associated with cognitive impairment at 13 months after acute stroke:
Previous stroke, higher IQCODE score (indicating poorer pre-stroke cognitive functioning), higher NIHSS score (indicating more severe strokes) and the presence of one or two e4-alleles. Executive function (mean changes (SD) between 3 and 27 months post stroke) Lowest -2.6 (4.3) 2nd -2.3 (5.9) 3rd -1.5 (3.6) Highest -1.7 (4.5) Language expression (mean changes (SD) between 3 and 27 months post stroke) 51% of elderly non-demented stroke patients have hyperhomocysteinaemia at 3 months post stroke. 79% of elderly stroke patients scored above 80 points on the CAMCOG at 27 months post stroke.
Found no associations between homocysteine levels and cognitive change, therefore 3 month post-stroke homocysteine measurement may not predict cognitive decline 2nd 14.1 (5.3) 3rd 15.0 (4.4) Highest 14. 5 (3.6) Language expression at 3 months post-stroke, study group by quartile homocysteine level Lowest 17.1 (2.0) 2nd 16.9 (2.2) 3rd 17.2 (1. 
